New drug shows promise for rare, destructive blood vessel disorder
NCT ID NCT04258046
First seen May 02, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tested the drug trametinib in 25 people aged 12 to 60 with complicated arteriovenous malformations (AVMs) that standard treatments often fail to control. The goal was to see if the drug could shrink the malformations, reduce symptoms, and improve quality of life. While not a cure, the treatment aims to manage the disease and prevent complications like bleeding and tissue damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS MALFORMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pediatric Dermatology Clinic at Stanford Children's Hospital
Palo Alto, California, 94304, United States
Conditions
Explore the condition pages connected to this study.